Article Text
Abstract
Rare diseases pose a particular priority setting problem. The UK gives rare diseases special priority in healthcare priority setting. Effectively, the National Health Service is willing to pay much more to gain a quality-adjusted life-year related to a very rare disease than one related to a more common condition. But should rare diseases receive priority in the allocation of scarce healthcare resources? This article develops and evaluates four arguments in favour of such a priority. These pertain to public values, luck egalitarian distributive justice the epistemic difficulties of obtaining knowledge about rare diseases and the incentives created by a higher willingness to pay. The first is at odds with our knowledge regarding popular opinion. The three other arguments may provide a reason to fund rare diseases generously. However, they are either overinclusive because they would also justify funding for many non-rare diseases or underinclusive in the sense of justifying priority for only some rare diseases. The arguments thus fail to provide a justification that tracks rareness as such.
- ethics
- health care for specific diseases/groups
- health economics
- philosophical ethics
- allocation of health care resources
Data availability statement
There are no data in this work.
Statistics from Altmetric.com
- ethics
- health care for specific diseases/groups
- health economics
- philosophical ethics
- allocation of health care resources
Data availability statement
There are no data in this work.
Footnotes
Presented at This paper was presented at the Danish Society for Philosophy Conference in Odense, 2020, and at the Measuring Health: Ethical Perspectives Workshop at Aarhus University, 2020.
Contributors AA is the sole author of this work.
Funding The work on this article has been funded by the Danish Research Council (grant number: 9037-00007B).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Should rare diseases get special treatment?
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year
- Solidarity, justice and unconditional access to healthcare
- A framework for luck egalitarianism in health and healthcare
- Rare neurological diseases: a practical approach to management
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Distributive justice and the harm to medical professionals fighting epidemics
- How the past matters for the future: a luck egalitarian sustainability principle for healthcare resource allocation
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence